178 related articles for article (PubMed ID: 15833065)
1. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
Doggrell SA
Expert Opin Investig Drugs; 2005 Mar; 14(3):339-42. PubMed ID: 15833065
[No Abstract] [Full Text] [Related]
2. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
3. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Gelfand EV; Cannon CP
Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
[TBL] [Abstract][Full Text] [Related]
4. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.
Colombo G; Orrù A; Lai P; Cabras C; Maccioni P; Rubio M; Gessa GL; Carai MA
Mol Neurobiol; 2007 Aug; 36(1):102-12. PubMed ID: 17952655
[TBL] [Abstract][Full Text] [Related]
5. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
6. Rimonabant--a selective CB1 antagonist.
Boyd ST; Fremming BA
Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
[TBL] [Abstract][Full Text] [Related]
7. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol.
López-Moreno JA; González-Cuevas G; Navarro M
Neurobiol Dis; 2007 Feb; 25(2):274-83. PubMed ID: 17067804
[TBL] [Abstract][Full Text] [Related]
8. Update on rimonabant--a selective cannabinoid CB1 antagonist.
Boyd ST; Fremming BA
Ann Pharmacother; 2006 May; 40(5):994. PubMed ID: 16638915
[No Abstract] [Full Text] [Related]
9. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
10. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu J; Sternon J
J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
[TBL] [Abstract][Full Text] [Related]
11. Peripherally restricted CB1 receptor blockers.
Chorvat RJ
Bioorg Med Chem Lett; 2013 Sep; 23(17):4751-60. PubMed ID: 23902803
[TBL] [Abstract][Full Text] [Related]
12. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.
Croci T; Landi M; Galzin AM; Marini P
Br J Pharmacol; 2003 Sep; 140(1):115-22. PubMed ID: 12967941
[TBL] [Abstract][Full Text] [Related]
13. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
[TBL] [Abstract][Full Text] [Related]
14. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
[TBL] [Abstract][Full Text] [Related]
15. Rimonabant: new data and emerging experience.
Wright SM; Dikkers C; Aronne LJ
Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
[TBL] [Abstract][Full Text] [Related]
16. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
17. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.
Maccioni P; Colombo G; Carai MA
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):55-9. PubMed ID: 20201816
[TBL] [Abstract][Full Text] [Related]
18. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.
Banasch M; Goetze O; Schmidt WE; Meier JJ
Liver Int; 2007 Oct; 27(8):1152-5. PubMed ID: 17845546
[No Abstract] [Full Text] [Related]
19. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
Le Foll B; Forget B; Aubin HJ; Goldberg SR
Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
[TBL] [Abstract][Full Text] [Related]
20. Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.
Cota D; Genghini S; Pasquali R; Pagotto U
J Endocrinol Invest; 2003 Oct; 26(10):1041-4. PubMed ID: 14759080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
